Vascular endothelial growth factor inhibitor-induced
hypertension: from pathophysiology to prevention and treatment
based on long-acting nitric oxide donors.

J 2014

Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.

KRUŽLIAK, Peter, Jan NOVÁK and Miroslav NOVÁK

Basic information

Original name

Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.

Authors

KRUŽLIAK, Peter (203 Czech Republic, guarantor), Jan NOVÁK (203 Czech Republic, belonging to the institution) and Miroslav NOVÁK (203 Czech Republic)

Edition

American Journal of Hypertension, Oxford, Oxford University Press, 2014, 0895-7061

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30105 Physiology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.852

RIV identification code

RIV/00216224:14110/14:00075844

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1093/ajh/hpt201

UT WoS

000328395500002

Keywords in English

NO donors; VEGF.; angiogenesis inhibitors; blood pressure; hypertension; nitric oxide (NO)

Abstract

V originále

Hypertension is the most common adverse effect of the inhibitors of vascular endothelial growth factor (VEGF) pathwaybased therapy (VEGF pathway inhibitors therapy, VPI therapy) in cancer patients. VPI includes monoclonal antibodies against VEGF, tyrosine kinase inhibitors, VEGF Traps, and so-called aptamers that may become clinically relevant in the future. All of these substances inhibit the VEGF pathway, which in turn causes a decrease in nitric oxide (NO) and an increase in blood pressure, with the consequent development of hypertension and its final events (e.g., myocardial infarction or stroke). To our knowledge, there is no current study on how to provide an optimal therapy for patients on VPI therapy with hypertension. This review summarizes the roles of VEGF and NO in vessel biology, provides an overview of VPI agents, and suggests a potential treatment procedure for patients with VPI-induced hypertension.

Citovat

KRUŽLIAK, Peter, Jan NOVÁK and Miroslav NOVÁK. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. American Journal of Hypertension. Oxford: Oxford University Press, 2014, vol. 27, No 1, p. 3-13. ISSN 0895-7061. Available from: https://dx.doi.org/10.1093/ajh/hpt201.

@article{1187261,
   author = {Kružliak, Peter and Novák, Jan and Novák, Miroslav},
   article_location = {Oxford},
   article_number = {1},
   doi = {http://dx.doi.org/10.1093/ajh/hpt201},
   keywords = {NO donors; VEGF.; angiogenesis inhibitors; blood pressure; hypertension; nitric oxide (NO)},
   language = {eng},
   issn = {0895-7061},
   journal = {American Journal of Hypertension},
   title = {Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.},
   volume = {27},
   year = {2014}
}

TY  - JOUR
ID  - 1187261
AU  - Kružliak, Peter - Novák, Jan - Novák, Miroslav
PY  - 2014
TI  - Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
JF  - American Journal of Hypertension
VL  - 27
IS  - 1
SP  - 3-13
EP  - 3-13
PB  - Oxford University Press
SN  - 08957061
KW  - NO donors
KW  - VEGF.
KW  - angiogenesis inhibitors
KW  - blood pressure
KW  - hypertension
KW  - nitric oxide (NO)
N2  - Hypertension is the most common adverse effect of the inhibitors of vascular endothelial growth factor (VEGF) pathwaybased therapy (VEGF pathway inhibitors therapy, VPI therapy) in cancer patients. VPI includes monoclonal antibodies against VEGF, tyrosine kinase inhibitors, VEGF Traps, and so-called aptamers that may become clinically relevant in the future. All of these substances inhibit the VEGF pathway, which in turn causes a decrease in nitric oxide (NO) and an increase in blood pressure, with the consequent development of hypertension and its final events (e.g., myocardial infarction or stroke). To our knowledge, there is no current study on how to provide an optimal therapy for patients on VPI therapy with hypertension. This review summarizes the roles of VEGF and NO in vessel biology, provides an overview of VPI agents, and suggests a potential treatment procedure for patients with VPI-induced hypertension.
ER  -

KRUŽLIAK, Peter, Jan NOVÁK and Miroslav NOVÁK. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. \textit{American Journal of Hypertension}. Oxford: Oxford University Press, 2014, vol.~27, No~1, p.~3-13. ISSN~0895-7061. Available from: https://dx.doi.org/10.1093/ajh/hpt201.

Detailed Information on Publication Record